Skip to main content
4SC AG logo

4SC AG — Investor Relations & Filings

Ticker · VSC ISIN · DE000A3E5C40 LEI · 391200QOKN7LGVP0RQ86 F Manufacturing
Open in API
Filings indexed 719 across all filing types
Latest filing 2011-04-27 Declaration of Voting R…
Country DE Germany
Listing F VSC

About 4SC AG

https://www.4sc.com/

4SC AG is a biopharmaceutical company that formerly focused on the research and development of small-molecule drugs for cancer treatment. The company's strategy centered on addressing diseases with high unmet medical needs by developing innovative therapies that targeted epigenetic mechanisms of action. According to the company's official statements, it currently has no products under development and no operational business.

Recent filings

Filing Released Lang Actions
Declaration of Voting Results & Voting Rights Announcements 2011
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Voting Rights Announcements' and explicitly states 'Veröffentlichung einer Stimmrechtsmitteilung' (Publication of a voting rights notification). It details that an individual, Wolfgang Egger, notified the company that his voting rights share in 4SC AG fell below certain thresholds (15% and 10%) and specifies the resulting percentage (9.427%). This directly corresponds to the definition of Declaration of Voting Results & Voting Rights Announcements (DVA), which covers official results from shareholder votes or related notifications like changes in voting power thresholds.
2011-04-27 German
4SC and Yakult Honsha Announce Exclusive License Agreement for Japan for the Oral HDAC Inhibitor Resminostat
Legal Proceedings Report Classification · 99% confidence The document is a press release dated April 14, 2011, announcing an exclusive license agreement between 4SC AG and Yakult Honsha for the drug resminostat in Japan. It details financial terms (upfront payment, milestones, royalties) and provides background information on the drug and the companies involved. This type of announcement, detailing a significant business transaction (licensing/alliance) that impacts future operations and potential revenue, fits best under the 'Capital/Financing Update' (CAP) category if it involves a major financial deal, or potentially 'Regulatory Filings' (RNS) as a general corporate announcement. However, since it is a specific announcement about a major strategic partnership involving significant financial considerations (EUR6 million upfront + up to EUR127 million milestones), it is more specific than a general RNS. It is not an earnings release (ER), an interim report (IR), or an annual report (10-K). Given the focus on a major licensing deal and associated payments, 'Capital/Financing Update' (CAP) is the most appropriate fit among the specific options, as licensing deals often fall under strategic financing/deal-making announcements.
2011-04-14 English
4SC Announces Exclusive License Agreement for Japan with Yakult Honsha for the Oral HDAC Inhibitor Resminostat
Regulatory Filings Classification · 100% confidence The document is titled 'Ad-hoc' and dated April 14, 2011. It announces a significant business event: an exclusive license agreement for Japan between 4SC AG and Yakult Honsha regarding the drug resminostat. This type of material announcement, which is not a full financial report (like 10-K or IR), a formal proxy statement (DEF 14A), or a transcript (CT), falls under the category of general corporate news or regulatory disclosure that doesn't fit a more specific financial or governance code. The text explicitly mentions dissemination as an 'Ad hoc announcement according to § 15 WpHG' (German Securities Trading Act). Since there is no specific code for 'Ad Hoc Announcement' that covers general material business developments, and it is not a formal report, the most appropriate fallback category is 'Regulatory Filings' (RNS), which serves as a general category for miscellaneous regulatory disclosures not covered elsewhere.
2011-04-14 English
4SC Announces Treatment of First Patient in Phase I TOPAS Study with the selective HDAC inhibitor 4SC-202
Regulatory Filings Classification · 100% confidence The document is a press release dated April 13, 2011, announcing that 4SC has treated the first patient in a Phase I clinical study (TOPAS) with their drug candidate 4SC-202. It details the study design, objectives (safety, pharmacokinetics, efficacy), and provides background on the drug and the company's pipeline. This type of announcement, focusing on clinical trial progress and pipeline updates, is not explicitly covered by the core financial filing types (10-K, ER, IR, etc.). It is a general corporate news item related to R&D progress. Since it is a specific corporate announcement that doesn't fit the other specialized categories (like M&A, Dividend, Management Change, etc.), the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general category for miscellaneous regulatory/corporate news disseminated via services like DGAP.
2011-04-13 English
4SC Announces Financial Results 2010
Earnings Release Classification · 100% confidence The document is titled "4SC Announces Financial Results 2010" and explicitly details the financial performance, including total revenue, R&D expenses, net loss, and cash flows for the year ended 31 December 2010. It provides key financial highlights and commentary on the results. This content strongly aligns with an Earnings Release (ER), which is the initial announcement of periodical financial results, often summarizing the key figures before the full, detailed report (like a 10-K or IR) is published. The text mentions that the "complete annual financial report will be available for download at www.4sc.com/Investors from 8:00 am CET," suggesting this document is the preliminary announcement, not the full annual report itself. Since it contains the core financial results announcement, ER is the most appropriate classification over RPA or RNS. FY 2010
2011-03-29 English
Annual Report 2010
Annual Report Classification · 100% confidence The document contains a comprehensive table of contents, a letter to shareholders, a management report, financial statements (IFRS), notes to the financial statements, and an auditor's report. It covers the full fiscal year 2010 and provides a detailed overview of company performance, strategy, and financial health. This structure is characteristic of an Annual Report (10-K). FY 2010
2011-03-29 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.